Company intelligence / Profile preview
Imunon, Inc.
Huntsville, Alabama, United Statesimunon.com ↗
- Ownership
- Public · IMNN
- Development stage
- Other
01
Overview
Developing DNA-based immunotherapies with lead program IMNN-001 for advanced ovarian cancer. As of September 2024, reported continued development with consistent net losses of $14.6 million for the first nine months of 2024.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- DNA-based immunotherapynucleic acid vaccines
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Multiple research institutions mentioned but not specifically named
04
Financials
- Market cap
- $5.1M
- Total revenue
- $0
- Enterprise value
- $6M
Beyond the preview
Go deeper on Imunon, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imunon, Inc..